State Drug Price Transparency Laws

TKG PACT Executive Briefings - 3-Minute Market Insights

Conteúdo fornecido por The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

1M ago 2:46

MP3•Home de episódios

Send us a Text Message.

Since 2016, 13 states have passed Drug Price Transparency Laws focused on enabling state policymakers to understand opaque drug pricing and payment systems to formulate policy solutions to high prices, while also creating the data infrastructure to realize those policy solutions.

Most of these state programs require reporting from manufacturers when they increase the Wholesale Acquisition Cost (WAC) of a drug above a certain threshold or if they introduce a drug with a high launch price.

Since 2020, 8 states have enacted Prescription Drug Affordability Boards often referred to as P-DABs, entities with the authority to review high cost drugs and in some states set an upper payment limit to ensure no one pays more than that amount in the state.
You may download the full TKG PACT Executive Briefing highlighted in this episode, at Executive Briefings | TKG PACT

We welcome your suggestions, ideas, and requests for Executive Briefing topics of interest. Please email us at Insights@thekinetixgroup.com.

49 episódios

#Fitness #Medicine #The Kinetix Group #Healthcare #Pharma #Voice #Triple Aim #Biotech #Health Management #Science #Alternative Health #Biology #Insight